8 years of historical data (2018–2025) · Healthcare · Drug Manufacturers - General
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Organon & Co. trades at 10.1x earnings, 60% above its 5-year average of 6.3x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 57%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.9B | $1.9B | $3.9B | $3.7B | $7.1B | $7.7B | — | — | — |
| Enterprise Value | $1.9B | $1.9B | $12.2B | $11.9B | $15.5B | $16.3B | — | — | — |
| P/E Ratio → | 10.13 | 9.96 | 4.48 | 3.61 | 7.78 | 5.71 | — | — | — |
| P/S Ratio | 0.30 | 0.30 | 0.60 | 0.59 | 1.15 | 1.22 | — | — | — |
| P/B Ratio | 2.10 | 2.06 | 8.19 | — | — | — | — | — | — |
| P/FCF | — | — | 6.58 | 6.87 | 16.54 | 3.92 | — | — | — |
| P/OCF | — | — | 4.12 | 4.63 | 8.31 | 3.14 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Organon & Co.'s enterprise value stands at 1.2x EBITDA, 82% below its 5-year average of 6.3x. The Healthcare sector median is 13.8x, placing the stock at a 92% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.30 | 1.91 | 1.91 | 2.52 | 2.59 | — | — | — |
| EV / EBITDA | 1.16 | 1.14 | 6.94 | 7.63 | 8.10 | 7.75 | — | — | — |
| EV / EBIT | 1.47 | 1.46 | 9.21 | 9.94 | 10.06 | 9.15 | — | — | — |
| EV / FCF | — | — | 20.80 | 22.18 | 36.04 | 8.30 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Organon & Co. earns an operating margin of 20.7%. ROE of 27.1% indicates solid capital efficiency. ROIC of 19.8% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.1% | 54.1% | 58.0% | 59.8% | 62.8% | 62.2% | 67.6% | 70.8% | 52.0% |
| Operating Margin | 20.7% | 20.7% | 23.2% | 21.2% | 27.6% | 30.4% | 43.6% | 49.5% | 27.7% |
| Net Profit Margin | 3.0% | 3.0% | 13.5% | 16.3% | 14.9% | 21.4% | 33.1% | 41.4% | 22.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 27.1% | 27.1% | 429.9% | — | — | 67.9% | 34.5% | 48.1% | 33.9% |
| ROA | — | — | 6.9% | 8.9% | 8.5% | 13.0% | 20.9% | 30.6% | 20.5% |
| ROIC | 19.8% | 19.8% | 13.1% | 12.7% | 17.5% | 22.8% | 34.4% | 43.9% | 32.5% |
| ROCE | — | — | 15.2% | 15.1% | 20.6% | 24.7% | 34.2% | 42.4% | 30.2% |
Solvency and debt-coverage ratios — lower is generally safer
Interest coverage of just 2.5x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 19.14 | — | — | — | 0.01 | 0.03 | 0.02 |
| Debt / EBITDA | — | — | 5.13 | 5.71 | 4.75 | 4.44 | 0.01 | 0.04 | 0.03 |
| Net Debt / Equity | — | 0.00 | 17.71 | — | — | — | 0.00 | -0.02 | -0.01 |
| Net Debt / EBITDA | — | 0.00 | 4.74 | 5.27 | 4.38 | 4.09 | 0.01 | -0.03 | -0.02 |
| Debt / FCF | — | — | 14.22 | 15.31 | 19.50 | 4.38 | 0.01 | -0.05 | -0.03 |
| Interest Coverage | 2.55 | 2.55 | 2.86 | 2.52 | 4.04 | 7.42 | 474.50 | 641.17 | — |
Short-term solvency ratios and asset-utilisation metrics
The current ratio has improved from 1.54x to 1.60x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | 1.60 | 1.54 | 1.56 | 1.45 | 1.33 | 2.95 | 2.40 |
| Quick Ratio | — | — | 1.11 | 1.09 | 1.17 | 1.10 | 0.99 | 2.15 | 1.76 |
| Cash Ratio | 0.25 | — | 0.25 | 0.24 | 0.28 | 0.28 | 0.00 | 0.24 | 0.16 |
| Asset Turnover | — | — | 0.49 | 0.52 | 0.56 | 0.59 | 0.65 | 0.74 | 0.93 |
| Inventory Turnover | 2.03 | — | 2.03 | 1.91 | 2.29 | 2.60 | 2.32 | 2.12 | 4.72 |
| Days Sales Outstanding | — | — | 84.99 | 108.22 | 94.94 | 87.54 | 78.51 | 73.83 | 59.47 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Organon & Co. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 9.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 7.7% | 8.0% | 4.1% | 1.9% | — | — | — |
| Payout Ratio | — | — | 34.4% | 28.7% | 31.6% | 10.7% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.9% | 10.0% | 22.3% | 27.7% | 12.9% | 17.5% | — | — | — |
| FCF Yield | — | — | 15.2% | 14.6% | 6.0% | 25.5% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.6% | 0.5% | 0.2% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 8.3% | 8.4% | 4.2% | 1.9% | — | — | — |
| Shares Outstanding | — | $261M | $259M | $256M | $255M | $254M | $254M | $253M | $253M |
Compare OGN with 2 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| OGNYou | $2B | 10.1 | 1.2 | — | 54.1% | 20.7% | 27.1% | 19.8% | — |
| NVS | $322B | 23.5 | 15.5 | 18.2 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
| SRXH | $9M | -0.2 | — | 7.6 | 19.9% | -4.9% | — | -18.1% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how OGN stacks up against sector leader Novartis AG.
Start ComparisonOrganon & Co.'s current P/E ratio is 10.1x. The historical average is 6.3x. This places it at the 100th percentile of its historical range.
Organon & Co.'s current EV/EBITDA is 1.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.3x.
Organon & Co.'s return on equity (ROE) is 27.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 106.9%.
Based on historical data, Organon & Co. is trading at a P/E of 10.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Organon & Co. has 54.1% gross margin and 20.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.